Vanda Pharmaceuticals (VNDA) EBITDA Margin (2010 - 2026)
Vanda Pharmaceuticals' (VNDA) quarterly EBITDA Margin came in at 96.58% in Q1 2026, down 1506.0% year-on-year from 6.87% in Q1 2025, and down 37.98% quarter-over-quarter from 70.0% in Q4 2025.
Vanda Pharmaceuticals (VNDA) EBITDA Margin (2010 - 2026) Analysis & Trends
Vanda Pharmaceuticals has disclosed EBITDA Margin across 17 years of filings, most recently posting 96.58% for Q1 2026.
- EBITDA Margin for Q1 2026 came in at 96.58%, down 1506.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 73.11% (down 3759.0% YoY), and the FY2025 annual result was 69.44%, down 4944.0% from the prior year.
- EBITDA Margin came in at 96.58% for Q1 2026 at Vanda Pharmaceuticals, down from 70.0% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 10.69% in Q4 2022 to a low of 96.58% in Q1 2026.
- The 5-year median for EBITDA Margin is 18.83% (2024), against an average of 28.09%.
- Across the five-year window, EBITDA Margin soared 1588 bps in 2023 and plunged 6250 bps in 2025, its largest moves.
- Vanda Pharmaceuticals' EBITDA Margin stood at 10.69% in 2022, then plunged by 242 bps to 15.22% in 2023, then fell by 24 bps to 18.83% in 2024, then slumped by 272 bps to 70.0% in 2025, then plunged by 38 bps to 96.58% in 2026.
- The last three EBITDA Margin figures came in at 96.58% (Q1 2026), 70.0% (Q4 2025), and 55.07% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Vanda Pharmaceuticals | 345.46 Mn | 143.15 Mn | 48.56 Mn | -96.58% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -96.58% |
| Dec 31, 2025 | -70.00% |
| Sep 30, 2025 | -55.07% |
| Jun 30, 2025 | -72.71% |
| Mar 31, 2025 | -81.53% |
| Dec 31, 2024 | -18.83% |
| Sep 30, 2024 | -22.63% |
| Jun 30, 2024 | -19.67% |
| Mar 31, 2024 | -19.02% |
| Dec 31, 2023 | -15.22% |
| Sep 30, 2023 | -14.93% |
| Jun 30, 2023 | -5.74% |
| Mar 31, 2023 | 3.67% |
| Dec 31, 2022 | 10.69% |
| Sep 30, 2022 | 6.44% |
| Jun 30, 2022 | 5.86% |
| Mar 31, 2022 | -12.20% |
| Dec 31, 2021 | 13.25% |
| Sep 30, 2021 | 15.92% |
| Jun 30, 2021 | 18.72% |